Clinical review pending
Menopause is the natural biological transition marked by the end of menstrual cycles, defined clinically as 12 consecutive months without a period. Perimenopause — the transition phase that precedes it — typically begins in a woman's 40s and lasts on average 4 to 8 years, while the average age of menopause in the United States is 51 (NIH National Institute on Aging, 2024). Common symptoms include hot flashes, night sweats, sleep disruption, mood changes, vaginal dryness, irregular periods, weight changes, and brain fog. The transition itself is not a disease, but symptoms can meaningfully reshape daily life and warrant a real clinical plan. Menopause may also be surgical (after bilateral oophorectomy) or medical (after chemotherapy or pelvic radiation), and those pathways carry their own risk-benefit considerations. At Viva Centers in Doral, FL, a qualified provider may discuss individualized evaluation, menopausal hormone therapy (MHT) per ACOG and the North American Menopause Society (NAMS), non-hormonal options and indicated bone-health assessment. Confirm provider scope, test location, visit language and follow-up availability; outside gynecology acceptance and handoff require confirmation.
Symptoms to Discuss
Symptoms vary widely — some women have years of meaningful vasomotor symptoms (hot flashes, night sweats), while others move through the transition almost asymptomatic. According to the North American Menopause Society (NAMS, 2024), 60 to 80 percent of women experience hot flashes, and symptoms last on average around 7 years (NIH, 2024). A qualified provider may ask about these symptom categories:
- Vasomotor symptoms — hot flashes, night sweats, flushing, palpitations
- Sleep disruption — middle-of-the-night waking, insomnia, fatigue
- Menstrual cycle changes in perimenopause — shorter, longer, skipped, or heavier periods
- Mood and cognitive changes — irritability, low mood, anxiety, brain fog
- Genitourinary symptoms — vaginal dryness, painful intercourse, urinary frequency or urgency
- Joint aches, decreased libido, and weight changes — especially abdominal weight gain
- Bone-density loss risk — most rapid in the first 5 years after menopause
How Menopause is Diagnosed
Menopause is primarily a clinical diagnosis in women in the typical age range — based on age, menstrual pattern, and symptoms, not on a hormone blood test (ACOG, 2024). Routine FSH (follicle-stimulating hormone) testing is not required to diagnose menopause in women over 45 with classic symptoms, although hormone testing can help when:
- A woman under 40 has irregular periods or vasomotor symptoms (to evaluate for premature ovarian insufficiency)
- A woman between 40 and 45 has cycle irregularity that could be explained by other causes
- The patient has had a hysterectomy and cannot use menstrual pattern to track the transition
- Other endocrine conditions are suspected (thyroid disease, hyperprolactinemia)
Hormone Therapy — A Balanced Conversation
Menopausal hormone therapy (MHT, sometimes called HT or HRT) remains the most effective treatment for moderate-to-severe hot flashes and the genitourinary syndrome of menopause, according to the 2022 NAMS position statement and ACOG. The Women's Health Initiative (WHI) study published in 2002 raised concerns about cardiovascular and breast cancer risk, but subsequent re-analyses and follow-up studies refined the picture: for healthy, symptomatic women under age 60 (or within 10 years of menopause onset), the benefits of systemic hormone therapy generally outweigh the risks. An individualized discussion with a qualified provider may cover:
- Personal and family history — breast cancer, blood clots, cardiovascular disease, stroke, liver disease
- Time-since-menopause and age — the so-called 'timing hypothesis' matters
- Symptom severity and how much it affects sleep, mood, work, and relationships
- Systemic vs. local options — systemic hormone therapy for vasomotor symptoms, vs. vaginal estrogen therapy for genitourinary symptoms only
- Route of administration — transdermal patches and gels carry lower blood-clot risk than oral tablets, per NAMS 2022
- Duration — there is no fixed stop date; the lowest effective dose for as long as benefits outweigh risks
- When MHT is not appropriate and what to use instead
Non-Hormonal Options for Hot Flashes and Mood
Many women cannot or prefer not to use systemic hormone therapy. Evidence-based non-hormonal options include:
- Cognitive behavioral therapy (CBT) — meta-analyses show meaningful reductions in hot-flash bother and improvement in sleep, per NAMS 2023
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) — established drug classes used at lower doses for vasomotor symptoms
- Anticonvulsant mood stabilizers and other non-hormonal prescriptions when appropriate
- Lifestyle adjustments — layered clothing, cool sleep environment, trigger identification, reduced alcohol and spicy-food intake
- Weight management and aerobic exercise — particularly effective for sleep, mood, and metabolic health
- Mind-body practices — paced breathing, mindfulness, yoga — supported by smaller but consistent trial data
Bone Health, Cardiovascular Risk, and DEXA Screening
Estrogen loss accelerates bone-density loss and shifts cardiovascular risk. A qualified provider may assess these risks according to age, symptoms and history. Confirm indicated tests, location and result ownership:
- Bone density (DEXA) scan — the U.S. Preventive Services Task Force recommends osteoporosis screening at age 65 for all women, and earlier (postmenopause through 64) for women with elevated fracture risk
- Vitamin D and calcium status — discuss whether assessment or supplementation is indicated
- Weight-bearing and resistance exercise — among the most effective non-pharmacologic interventions for bone density
- Lipid panel and blood pressure — cardiovascular risk increases at menopause, and lipid management starts earlier when MHT is being considered
- Discussion of fracture-risk tools (FRAX) when DEXA results are borderline
- Referral planning — discuss outside gynecology or endocrinology assessment when needed; confirm acceptance and timing
When to Book a Menopause Visit
Do not wait until symptoms become unmanageable. Early evaluation often changes the trajectory of the transition and the long-term health plan:
- When hot flashes, night sweats, or sleep loss disrupt work, mood, or relationships
- When perimenopausal cycle changes feel unusual — very heavy bleeding, post-coital bleeding, or bleeding after 12 months of amenorrhea always needs evaluation
- When the question of hormone therapy keeps coming up and you want an evidence-based conversation
- When vaginal dryness or painful intercourse affects your quality of life — vaginal estrogen therapy is very effective and is considered safe for most women, even those with a personal history of breast cancer when discussed with their oncology team
- When you want a baseline DEXA, lipid panel, and cardiovascular risk assessment
- When you are bilingual and want a provider who can explain options fully in either English or Spanish
Language and follow-up arrangements
- Confirm the initial visit format; a provider determines whether examination, labs or outside DEXA assessment is indicated
- Follow-up format — confirm whether an in-person or remote visit is available and clinically suitable
- Appointments — confirm current availability before scheduling
- Discuss outside gynecology or bone-health assessment when indicated; confirm acceptance and handoff
- Confirm booking options and whether portal support is available, including hours and response expectations
- Confirm which visits, written instructions and follow-up resources are available in English or Spanish
Sources
- ACOG — Menopause and Hormone Therapy Resources — American College of Obstetricians and Gynecologists
- NIH National Institute on Aging — Menopause Overview — NIH National Institute on Aging
- North American Menopause Society — Patient Education — The North American Menopause Society (NAMS)
- USPSTF — Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons — U.S. Preventive Services Task Force
- NIH Women's Health Initiative — Study Overview — NIH National Heart, Lung, and Blood Institute
Frequently Asked Questions
How is menopause diagnosed?
Menopause is primarily a clinical diagnosis — based on age, menstrual pattern, and symptoms, not a hormone blood test. In women over 45 with typical symptoms, FSH testing is generally not required per ACOG. A qualified provider may consider hormone or thyroid testing when a woman is under 45, has had a hysterectomy, or has symptoms that could overlap with other endocrine conditions. The diagnostic standard for natural menopause is 12 consecutive months without a period.
What is the difference between perimenopause and menopause?
Perimenopause is the transitional phase before menopause when hormone levels fluctuate. It typically starts in the early to mid-40s and lasts 4 to 8 years on average. Symptoms include irregular periods, hot flashes, sleep disruption, and mood changes. Menopause is defined as 12 consecutive months without a period — the average age in the U.S. is 51 (NIH National Institute on Aging, 2024). Post-menopause is everything after that 12-month mark.
Is hormone therapy safe?
For healthy, symptomatic women under age 60 or within 10 years of menopause onset, the benefits of menopausal hormone therapy generally outweigh the risks, per the 2022 NAMS position statement and ACOG. The Women's Health Initiative study from 2002 originally raised concerns, but later analyses showed risk varies meaningfully by age, time-since-menopause, route, and personal history. A qualified provider may review your individual risk profile — breast cancer history, cardiovascular risk, blood-clot history, liver disease — and discuss systemic vs. local (vaginal) therapy, transdermal vs. oral routes, and duration.
What were the Women's Health Initiative (WHI) findings, in plain terms?
The WHI was a large randomized trial that, in 2002, reported increased risks of breast cancer and cardiovascular events in women taking combined oral hormone therapy. Subsequent re-analyses showed those risks were concentrated in older women who started therapy many years after menopause. For younger, recently menopausal women, the absolute risks were small and benefits for symptom relief, bone density, and possibly cardiovascular health emerged. ACOG and NAMS now recommend individualized decision-making — not a blanket avoidance of hormone therapy.
What non-hormonal options work for hot flashes?
Evidence-based non-hormonal options include cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) used at lower-than-depression doses, anticonvulsant medications when appropriate, paced breathing, weight management, layered clothing, and lifestyle adjustments. Per NAMS 2023, CBT, certain SSRIs/SNRIs, and a newer non-hormonal class of medication have the strongest data. A qualified provider can assess which options fit your history; confirm treatment scope and outside referral availability.
Should I get a DEXA bone density scan?
The U.S. Preventive Services Task Force (USPSTF) recommends osteoporosis screening at age 65 for all women, and earlier for postmenopausal women with elevated fracture risk — for example, a low body weight, family history of hip fracture, smoking, long-term steroid use, or early menopause before age 45. Bone density loss is most rapid in the first 5 years after menopause, so a qualified provider may consider earlier assessment when risk factors are present; confirm indication and outside test access.
How does menopause affect cardiovascular risk?
Cardiovascular risk in women rises at and after menopause as estrogen levels fall. A qualified provider may assess blood pressure, lipids, body composition, family history, diabetes risk and smoking status; tests are individualized. Lifestyle changes — aerobic exercise, dietary patterns such as Mediterranean-style eating, weight management — remain first-line. Statin and antihypertensive decisions follow USPSTF and AHA guidance. When MHT is being considered, the cardiovascular risk profile guides choice of route (transdermal vs. oral) and timing.
Do you offer bilingual menopause care?
Ask which English or Spanish visit and written education resources are available. Confirm remote care and portal support separately.
Does insurance cover menopause care?
Confirm provider availability, test location, referrals, costs and insurance coverage before scheduling. Testing or specialist care may take place outside Viva; acceptance and timing require confirmation.
When should I worry — what symptoms need urgent evaluation?
Heavy or prolonged bleeding in perimenopause, any bleeding after 12 months of amenorrhea (post-menopausal bleeding), severe chest pain, sudden severe headache, leg swelling or pain that could suggest a blood clot, and new neurologic symptoms always need urgent evaluation. For these, do not wait for a routine appointment — seek prompt clinical advice or go directly to emergency care for severe symptoms.